<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hypophosphatemia: Causes of hypophosphatemia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hypophosphatemia: Causes of hypophosphatemia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hypophosphatemia: Causes of hypophosphatemia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan S L Yu, MB, BChir</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jason R Stubbs, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Emmett, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard H Sterns, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 07, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The reported prevalence of hypophosphatemia varies widely, depending upon the patient population surveyed and the concentration of serum phosphorus used to define hypophosphatemia. Up to 5 percent of hospitalized patients may have low serum phosphate concentrations (less than 2.5 mg/dL [0.80 mmol/L]), although prevalences of over 30 to 50 percent have been reported in patients with alcohol use disorder and patients with severe sepsis or trauma [<a href="#rid1">1-3</a>]. Profound hypophosphatemia (less than 1 mg/dL [0.32 mmol/L]), which can lead to physiological disturbances and symptoms, is much less common [<a href="#rid3">3-5</a>]. (See  <a class="medical medical_review" href="/d/html/847.html" rel="external">"Hypophosphatemia: Clinical manifestations of phosphate depletion"</a>.)</p><p>There are four major mechanisms by which hypophosphatemia can occur  (<a class="graphic graphic_table graphicRef71616" href="/d/graphic/71616.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Redistribution of phosphate from the extracellular fluid into cells</p><p class="bulletIndent1"><span class="glyph">●</span>Decreased intestinal absorption of phosphate</p><p class="bulletIndent1"><span class="glyph">●</span>Increased urinary phosphate excretion</p><p class="bulletIndent1"><span class="glyph">●</span>Removal by kidney replacement therapies</p><p></p><p>The causes of hypophosphatemia will be reviewed here. The diagnosis and treatment of hypophosphatemia are discussed separately. (See  <a class="medical medical_review" href="/d/html/835.html" rel="external">"Hypophosphatemia: Evaluation and treatment"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">INTERNAL REDISTRIBUTION</span><span class="headingEndMark"> — </span>Stimulation of glycolysis increases the formation of phosphorylated carbohydrate compounds in the liver and skeletal muscle. The source of this phosphate is the inorganic phosphate in the extracellular fluid; as a result, serum phosphate concentrations (and urinary phosphate excretion) fall rapidly. This occurs in several situations.</p><p class="headingAnchor" id="H3"><span class="h2">Increased insulin secretion, particularly during refeeding</span><span class="headingEndMark"> — </span>In normal subjects, the administration of insulin or glucose (which stimulates endogenous insulin release) results in only a small decrease in serum phosphate concentrations. Administration of <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">glucagon</a> and <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> can also cause mild hypophosphatemia by a similar mechanism.</p><p>If, however, there is underlying phosphate depletion, severe hypophosphatemia may ensue. It is most likely to occur during treatment of patients with diabetic ketoacidosis or nonketotic hyperglycemia (in which the glucose-induced osmotic diuresis results in loss of phosphate in the urine); during carbohydrate refeeding in malnourished patients with alcoholism or anorexia nervosa [<a href="#rid6">6,7</a>]; and in patients receiving hyperalimentation. Concurrent respiratory alkalosis may also contribute in patients with alcohol use disorder. (See  <a class="medical medical_review" href="/d/html/1792.html" rel="external">"Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Clinical features, evaluation, and diagnosis", section on 'Serum phosphate'</a> and  <a class="medical medical_review" href="/d/html/2094.html" rel="external">"Eating disorders: Overview of prevention and treatment"</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Acute respiratory alkalosis</span><span class="headingEndMark"> — </span>The fall in partial pressure of carbon dioxide during acute respiratory alkalosis results in a similar change in the cells because carbon dioxide readily diffuses across cell membranes. The resulting rise in intracellular pH stimulates phosphofructokinase activity which in turn stimulates glycolysis [<a href="#rid8">8</a>]. Extreme hyperventilation (to PCO2 &lt;20 mmHg) in normal subjects can lower serum phosphate concentrations to below 1 mg/dL (0.32 mmol/L) [<a href="#rid9">9</a>], and it is probably the most common cause of marked hypophosphatemia in hospitalized patients [<a href="#rid4">4</a>]. Less pronounced hypophosphatemia may occur during the increase in ventilation after successful treatment of severe asthma [<a href="#rid10">10</a>]. The effects of mild respiratory alkalosis to induce falls in serum phosphate of &gt;0.3 mg/dL require concomitant glucose infusions and may persist after hyperventilation ceases [<a href="#rid11">11</a>].</p><p>Respiratory alkalosis also may be the precipitating factor in the hypophosphatemia-induced acute rhabdomyolysis that can occur in patients with alcohol use disorder. In these patients, however, the underlying hypophosphatemia may be masked initially due to the release of phosphate from the injured muscle cells.</p><p class="headingAnchor" id="H5"><span class="h2">Hungry bone syndrome</span><span class="headingEndMark"> — </span>Parathyroidectomy (for primary or tertiary hyperparathyroidism) or, rarely, thyroidectomy (for hyperthyroidism) in patients with preexisting osteopenia can result in marked sequestration of calcium and phosphate in bone in the immediate postoperative period. This phenomenon, called the hungry bone syndrome, may be associated with significant hypocalcemia (which may be symptomatic) and hypophosphatemia. A similar phenomenon may occur after treatment with <a class="drug drug_general" data-topicid="8850" href="/d/drug information/8850.html" rel="external">cinacalcet</a> [<a href="#rid12">12</a>], which decreases parathyroid hormone (PTH) release from the parathyroid gland, or <a class="drug drug_general" data-topicid="15575" href="/d/drug information/15575.html" rel="external">denosumab</a> [<a href="#rid13">13</a>], which reduces bone resorption by inhibiting osteoclast activity. (See  <a class="medical medical_review" href="/d/html/2070.html" rel="external">"Hungry bone syndrome following parathyroidectomy in patients with end-stage kidney disease"</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">DECREASED INTESTINAL ABSORPTION</span><span class="headingEndMark"> — </span>Normal adults are in phosphate balance. Their dietary intake of phosphate, which usually ranges from 800 to 1500 mg/day, is usually well in excess of gastrointestinal losses, and, therefore, variations in intake usually have little effect on phosphate homeostasis. There is little regulation of gut absorption (although calcitriol, the most active metabolite of vitamin D, does have some stimulatory effect). Approximately 80 percent of dietary phosphate is absorbed in the small intestine. In addition, 150 to 200 mg/day is secreted in the colon.</p><p class="headingAnchor" id="H7"><span class="h2">Inadequate intake</span><span class="headingEndMark"> — </span>Poor intake alone is rarely responsible for severe phosphate depletion because of rapid renal adaptation, whereby renal tubular phosphate reabsorption approaches 100 percent, and, therefore, urinary phosphate excretion approaches zero [<a href="#rid14">14,15</a>]. If, however, phosphate deprivation is prolonged and severe (intake of less than 100 mg/day), then continued colonic phosphate secretion can lead to hypophosphatemia. More often, poor intake is combined with chronic diarrhea to cause markedly negative phosphate balance. These patients may also have poor intake or malabsorption of vitamin D. The secondary hyperparathyroidism induced by vitamin D deficiency can worsen phosphate depletion by increasing urinary phosphate excretion. (See <a class="local">'Increased urinary excretion'</a> below.)</p><p>Total starvation alone does not cause hypophosphatemia, because of the lack of insulin and the associated increase in cell catabolism that results in phosphate release from cells. Refeeding of starved patients, however, can cause hypophosphatemia, unless phosphate is provided.</p><p class="headingAnchor" id="H8"><span class="h2">Medications</span><span class="headingEndMark"> — </span>There are several drugs that can inhibit the intestinal absorption of phosphate, producing an associated reduction in serum phosphate. Antacids, particularly those that are aluminum and magnesium based, cause net loss of phosphate from the body by binding to both ingested and secreted phosphate, with the resulting formation of insoluble aluminum or magnesium phosphate salts. Prolonged high-dose treatment with these drugs can cause hypophosphatemia, osteomalacia, and myopathy [<a href="#rid16">16</a>]. This has become less of a problem since the availability of other, more convenient drugs to treat acid-peptic disease, such as histamine H2-receptor blockers and proton pump inhibitors. Hypophosphatemia related to prior antacid use is a particular problem postoperatively in patients who undergo hepatic resection [<a href="#rid17">17</a>]. Various phosphate binders are used to treat hyperphosphatemia in patients with advanced kidney disease, and inappropriate or excessive use in that population (particularly in malnourished patients) may induce hypophosphatemia. (See  <a class="medical medical_review" href="/d/html/1942.html" rel="external">"Management of hyperphosphatemia in adults with chronic kidney disease"</a>.)</p><p><a class="drug drug_general" data-topicid="9695" href="/d/drug information/9695.html" rel="external">Niacin</a> and its derivatives can also promote fecal phosphate losses by reducing intestinal expression of the type 2b sodium-phosphate cotransporter (NaPi-IIb) [<a href="#rid18">18,19</a>]; however, overt hypophosphatemia is rarely observed when these drugs are taken at commonly prescribed doses.</p><p class="headingAnchor" id="H9"><span class="h2">Steatorrhea and chronic diarrhea</span><span class="headingEndMark"> — </span>Steatorrhea or chronic diarrhea can cause mild to moderate hypophosphatemia due to decreased phosphate absorption from the gut and renal phosphate wasting, the latter caused by secondary hyperparathyroidism induced by concomitant vitamin D deficiency.</p><p class="headingAnchor" id="H10"><span class="h1">INCREASED URINARY EXCRETION</span><span class="headingEndMark"> — </span>The kidney exerts a major influence on phosphate balance. Renal phosphate transport occurs in the proximal tubule (60 to 70 percent of the filtered load being reabsorbed) and in the distal tubule (10 to 15 percent of the filtered load being reabsorbed) [<a href="#rid14">14,15</a>]. Phosphate reabsorption is linked to sodium reabsorption via sodium-phosphate cotransporters in the luminal membrane. These transporters use the favorable inward concentration gradient for sodium (the cell sodium concentration is less than 25 mEq/L, well below the 145 mEq/L concentration in the tubular lumen) to drive the active reabsorption of phosphate.</p><p>Physiologic regulators of renal tubular phosphate reabsorption include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Serum phosphate concentration – Mild phosphate depletion stimulates phosphate reabsorption via the sodium-phosphate cotransporters in the proximal tubule [<a href="#rid14">14,15</a>]. Phosphate depletion also leads to increased synthesis of new transporters, which increases tubular phosphate reabsorption.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Parathyroid hormone (PTH) – PTH increases phosphate excretion by diminishing activity of sodium-phosphate cotransporters [<a href="#rid14">14,15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Phosphatonins – Phosphatonins such as fibroblast growth factor 23 (FGF-23), fibroblast growth factor 7 (FGF-7), matrix extracellular phosphoglycoprotein (MEPE), and secreted frizzled-related protein-4 (sFRP-4) decrease phosphate reabsorption by sodium-phosphate cotransporters [<a href="#rid20">20-24</a>].</p><p></p><p>It has been suggested that gastrointestinal or bone sensors of dietary phosphate may lead to direct enhancement of renal phosphate excretion by an undefined mechanism [<a href="#rid25">25</a>], but this remains an area in need of further investigation.</p><p>The hypophosphatemia-induced increase in phosphate reabsorption protects against further phosphate losses. If inappropriately increased excretion persists, it is due to one of two factors:</p><p class="bulletIndent1"><span class="glyph">●</span>The presence of a circulating factor promoting urinary phosphate losses, such as PTH or one of the aforementioned phosphatonins (eg, FGF-23)</p><p class="bulletIndent1"><span class="glyph">●</span>An intrinsic defect in phosphate transport</p><p></p><p class="headingAnchor" id="H11"><span class="h2">Primary and secondary hyperparathyroidism</span><span class="headingEndMark"> — </span>Any cause of hypersecretion of PTH can lead to hypophosphatemia. This occurs in primary hyperparathyroidism (in which hypercalcemia is usually the most prominent abnormality) and in secondary hyperparathyroidism induced by any of the causes of vitamin D deficiency. Most patients with primary hyperparathyroidism have mild hypophosphatemia. It may be more severe in those with vitamin D deficiency and secondary hyperparathyroidism because they have not only increased urinary phosphate excretion, but also decreased gastrointestinal phosphate absorption. Animal models suggest that the mechanism by which this occurs may be due, in part, to a PTH-induced increase in FGF-23 [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H12"><span class="h2">Vitamin D deficiency or resistance</span><span class="headingEndMark"> — </span>Vitamin D deficiency can cause hypophosphatemia both by decreasing gastrointestinal phosphate absorption and by causing hypocalcemia and secondary hyperparathyroidism, resulting in increased urinary phosphate excretion. Vitamin D deficiency can occur as a result of decreased intake or absorption, reduced sun exposure, increased hepatic catabolism, decreased endogenous synthesis, or end-organ resistance  (<a class="graphic graphic_table graphicRef58837" href="/d/graphic/58837.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/2048.html" rel="external">"Causes of vitamin D deficiency and resistance"</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Primary renal phosphate wasting</span><span class="headingEndMark"> — </span>There are several rare syndromes characterized by isolated renal phosphate wasting. The resulting hypophosphatemia is the primary cause of rickets, and, in contrast to vitamin D deficiency or resistance, hypocalcemia is not present.</p><p>The underlying abnormalities of some of these syndromes have been characterized [<a href="#rid27">27</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In X-linked hypophosphatemic rickets (which had been called vitamin D-resistant rickets), the defect in proximal tubular phosphate transport is due to a mutation in the PHEX gene [<a href="#rid28">28</a>]. This gene encodes an endopeptidase that indirectly alters the degradation and production of FGF-23, a phosphatonin that promotes urinary phosphate excretion and suppresses calcitriol synthesis. (See  <a class="medical medical_review" href="/d/html/5802.html" rel="external">"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia", section on 'X-linked hypophosphatemia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A few reports have described a renal phosphate wasting syndrome with rickets or osteomalacia that is transmitted as an autosomal dominant trait. This disorder is known as autosomal dominant hypophosphatemic rickets and results from mutations in the FGF-23 gene on chromosome 12p13. This mutant form of FGF-23 is resistant to protease cleavage but retains its phosphaturic properties [<a href="#rid29">29</a>]. (See  <a class="medical medical_review" href="/d/html/5802.html" rel="external">"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia", section on 'Autosomal dominant hypophosphatemia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A number of autosomal recessive mutations have been described that result in hypophosphatemia associated with various other clinical manifestations:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mutations in the sodium-phosphate cotransporter gene SLC34A3 produce striking dysfunction of the type 2c sodium-phosphate cotransporter and lead to hereditary hypophosphatemic rickets with accompanying hypercalciuria [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mutations in the SLC34A1 gene encoding the type 2a sodium-phosphate cotransporter are associated with hypophosphatemia in conjunction with nephrolithiasis and osteomalacia, although the exact mechanisms responsible for these clinical manifestations remain elusive [<a href="#rid31">31,32</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Defects in the sodium-hydrogen exchanger regulatory factor 1 (NHERF1) are associated with impaired phosphate reabsorption and hypophosphatemia [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mutations in the genes encoding dentin matrix protein 1 [<a href="#rid34">34,35</a>], ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) [<a href="#rid36">36</a>], and klotho [<a href="#rid37">37</a>] are also linked to hypophosphatemic syndromes in humans. (See  <a class="medical medical_review" href="/d/html/5802.html" rel="external">"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia", section on 'Hypophosphatemic rickets with hypercalciuria'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A similar syndrome occurs as an acquired disorder in patients with tumor-induced osteomalacia. These patients usually have tumors of mesenchymal origin, often a sclerosing type of hemangiopericytoma, that produce a phosphaturic hormone(s) [<a href="#rid38">38</a>]. Among the factors that may be important are FGF-23, MEPE, and sFRP-4. (See  <a class="medical medical_review" href="/d/html/5802.html" rel="external">"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia", section on 'Tumor-induced osteomalacia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rarely, significant renal phosphate wasting is observed in patients with fibrous dysplasia and/or McCune-Albright syndrome, disorders that result from mutations in the alpha subunit of the stimulatory G protein. Excess production of FGF-23 has been found in some of these patients [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypophosphatemia is a common complication following kidney transplantation and may be due in part to tertiary hyperparathyroidism [<a href="#rid40">40-42</a>]. Elevated levels of FGF-23 may also contribute to this complication [<a href="#rid43">43</a>]. It appears to resolve by one year post-transplantation [<a href="#rid44">44</a>]. (See  <a class="medical medical_review" href="/d/html/7299.html" rel="external">"Kidney transplantation in adults: Persistent hyperparathyroidism after kidney transplantation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypophosphatemia and hyperphosphaturia are common in patients who have undergone a partial hepatectomy [<a href="#rid22">22,45,46</a>]. The mechanism is not known [<a href="#rid22">22,46</a>].</p><p></p><p class="headingAnchor" id="H14"><span class="h2">Fanconi syndrome</span><span class="headingEndMark"> — </span>The Fanconi syndrome refers to a generalized impairment in proximal tubular function leading to urinary wasting of compounds normally reabsorbed in the proximal tubule. The consequences are hypophosphatemia (which can lead to osteomalacia), glucosuria, hypouricemia, aminoaciduria, and proximal renal tubular acidosis due to bicarbonate loss in the urine [<a href="#rid47">47</a>]. Serum calcitriol concentrations are either low or inappropriately normal.</p><p>The Fanconi syndrome is rare in adults. It is most often due to multiple myeloma (in which the immunoglobulin light chains are toxic to the renal tubules) or medications (such as tenofovir). In children, cystinosis, Wilson's disease, and hereditary fructose intolerance are the most common causes of this syndrome. (See  <a class="medical medical_review" href="/d/html/2328.html" rel="external">"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis"</a>.)</p><p class="headingAnchor" id="H15"><span class="h2">Miscellaneous</span><span class="headingEndMark"> — </span>Other factors that can increase urinary phosphate excretion are osmotic diuresis (most often due to glucosuria); proximally acting diuretics (<a class="drug drug_general" data-topicid="9268" href="/d/drug information/9268.html" rel="external">acetazolamide</a> and some thiazide diuretics that also have carbonic anhydrase inhibitory activity, such as <a class="drug drug_general" data-topicid="9644" href="/d/drug information/9644.html" rel="external">metolazone</a>); acute volume expansion (which diminishes proximal sodium reabsorption); and intravenous iron administration [<a href="#rid48">48,49</a>]. Intravenous iron formulations containing carbohydrate moieties may increase phosphate excretion by causing an increase in circulating levels of FGF-23 [<a href="#rid50">50,51</a>]. (See <a class="local">'Primary renal phosphate wasting'</a> above.)</p><p>Increased urinary phosphate excretion and hypophosphatemia have also been reported with several classes of chemotherapeutic agents, including tyrosine-kinase inhibitors (particularly, <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a> mesylate) [<a href="#rid52">52,53</a>], mammalian (mechanistic) target of rapamycin (mTOR) inhibitors (especially <a class="drug drug_general" data-topicid="10344" href="/d/drug information/10344.html" rel="external">temsirolimus</a>) [<a href="#rid54">54,55</a>], and vascular endothelial growth factor (VEGF) inhibitors (such as <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>) [<a href="#rid56">56</a>]. The mechanisms remain uncertain.</p><p class="headingAnchor" id="H476998503"><span class="h1">KIDNEY REPLACEMENT THERAPY</span><span class="headingEndMark"> — </span>Hypophosphatemia is observed in many patients receiving continuous kidney replacement therapy [<a href="#rid57">57</a>], largely due to removal of phosphate with the effluent waste. This is particularly problematic when utilizing aggressive kidney replacement prescriptions containing high dialysate or replacement fluid flow rates. The increased utilization of intravenous phosphate for repletion of hypophosphatemia in patients receiving continuous kidney replacement therapy has likely contributed to shortages of intravenous phosphate preparations in the United States.</p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview </strong>– The four major mechanisms that cause hypophosphatemia include the redistribution of phosphate from the extracellular fluid into cells, decreased intestinal absorption of phosphate, increased urinary phosphate excretion, and removal by kidney replacement therapies. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Internal redistribution </strong>– The redistribution of phosphate occurs as a result of the stimulation of glycolysis by the administration of insulin, glucose, <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">glucagon</a>, and <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a>; during acute respiratory alkalosis; and as a result of hungry bone syndrome following parathyroidectomy or thyroidectomy in patients with preexisting osteopenia. (See <a class="local">'Internal redistribution'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Decreased intestinal absorption </strong>– Decreased intestinal absorption of phosphate may be caused by poor intake combined with chronic diarrhea or by prolonged use of antacids or phosphate binders that sequester both ingested and secreted phosphate. Poor intake alone is rarely a cause of significant hypophosphatemia. (See <a class="local">'Decreased intestinal absorption'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased urinary excretion </strong>– Increased urinary excretion of phosphate occurs as a result of hyperparathyroidism, vitamin D deficiency, and several rare syndromes that cause isolated renal phosphate wasting. The Fanconi syndrome is a generalized impairment in proximal tubular function that causes urinary wasting of phosphate as well as other compounds. In adults, the Fanconi syndrome is most often due to multiple myeloma; in children, cystinosis, Wilson's disease, and hereditary fructose intolerance are the most common causes of the syndrome. Other factors that may increase urinary phosphate excretion include osmotic diuresis, proximally acting diuretics, acute volume expansion, intravenous iron administration, and several chemotherapeutic agents. (See <a class="local">'Increased urinary excretion'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kidney replacement therapy </strong>– Hypophosphatemia is observed in many patients receiving continuous kidney replacement therapy, largely due to removal of phosphate with the effluent waste. (See <a class="local">'Kidney replacement therapy'</a> above.)</p><p></p><p class="headingAnchor" id="H15588904"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Zalman S Agus, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Larsson L, Rebel K, Sörbo B. Severe hypophosphatemia--a hospital survey. Acta Med Scand 1983; 214:221.</a></li><li><a class="nounderline abstract_t">King AL, Sica DA, Miller G, Pierpaoli S. Severe hypophosphatemia in a general hospital population. South Med J 1987; 80:831.</a></li><li><a class="nounderline abstract_t">Gaasbeek A, Meinders AE. Hypophosphatemia: an update on its etiology and treatment. Am J Med 2005; 118:1094.</a></li><li><a class="nounderline abstract_t">Halevy J, Bulvik S. Severe hypophosphatemia in hospitalized patients. Arch Intern Med 1988; 148:153.</a></li><li><a class="nounderline abstract_t">Subramanian R, Khardori R. Severe hypophosphatemia. Pathophysiologic implications, clinical presentations, and treatment. Medicine (Baltimore) 2000; 79:1.</a></li><li><a class="nounderline abstract_t">Paterson CR. Hypophosphataemia: a dangerous disorder. Nutrition 1996; 12:540.</a></li><li><a class="nounderline abstract_t">Marinella MA. Refeeding syndrome and hypophosphatemia. J Intensive Care Med 2005; 20:155.</a></li><li><a class="nounderline abstract_t">Brautbar N, Leibovici H, Massry SG. On the mechanism of hypophosphatemia during acute hyperventilation: evidence for increased muscle glycolysis. Miner Electrolyte Metab 1983; 9:45.</a></li><li><a class="nounderline abstract_t">MOSTELLAR ME, TUTTLE EP Jr. EFFECTS OF ALKALOSIS ON PLASMA CONCENTRATION AND URINARY EXCRETION OF INORGANIC PHOSPHATE IN MAN. J Clin Invest 1964; 43:138.</a></li><li><a class="nounderline abstract_t">Laaban JP, Waked M, Laromiguiere M, et al. Hypophosphatemia complicating management of acute severe asthma. Ann Intern Med 1990; 112:68.</a></li><li><a class="nounderline abstract_t">Paleologos M, Stone E, Braude S. Persistent, progressive hypophosphataemia after voluntary hyperventilation. Clin Sci (Lond) 2000; 98:619.</a></li><li><a class="nounderline abstract_t">Nowack R, Wachtler P. Hypophosphatemia and hungry bone syndrome in a dialysis patient with secondary hyperparathyroidism treated with cinacalcet--proposal for an improved monitoring. Clin Lab 2006; 52:583.</a></li><li><a class="nounderline abstract_t">Fizazi K, Bosserman L, Gao G, et al. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. J Urol 2009; 182:509.</a></li><li><a class="nounderline abstract_t">Murer H. Homer Smith Award. Cellular mechanisms in proximal tubular Pi reabsorption: some answers and more questions. J Am Soc Nephrol 1992; 2:1649.</a></li><li><a class="nounderline abstract_t">Murer H, Lötscher M, Kaissling B, et al. Renal brush border membrane Na/Pi-cotransport: molecular aspects in PTH-dependent and dietary regulation. Kidney Int 1996; 49:1769.</a></li><li><a class="nounderline abstract_t">Lotz M, Zisman E, Bartter FC. Evidence for a phosphorus-depletion syndrome in man. N Engl J Med 1968; 278:409.</a></li><li><a class="nounderline abstract_t">Buell JF, Berger AC, Plotkin JS, et al. The clinical implications of hypophosphatemia following major hepatic resection or cryosurgery. Arch Surg 1998; 133:757.</a></li><li><a class="nounderline abstract_t">Maccubbin D, Tipping D, Kuznetsova O, et al. Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial. Clin J Am Soc Nephrol 2010; 5:582.</a></li><li><a class="nounderline abstract_t">Ix JH, Ganjoo P, Tipping D, et al. Sustained hypophosphatemic effect of once-daily niacin/laropiprant in dyslipidemic CKD stage 3 patients. Am J Kidney Dis 2011; 57:963.</a></li><li><a class="nounderline abstract_t">Antoniucci DM, Yamashita T, Portale AA. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 2006; 91:3144.</a></li><li><a class="nounderline abstract_t">Miyamoto K, Ito M, Tatsumi S, et al. New aspect of renal phosphate reabsorption: the type IIc sodium-dependent phosphate transporter. Am J Nephrol 2007; 27:503.</a></li><li><a class="nounderline abstract_t">Nafidi O, Lapointe RW, Lepage R, et al. Mechanisms of renal phosphate loss in liver resection-associated hypophosphatemia. Ann Surg 2009; 249:824.</a></li><li><a class="nounderline abstract_t">Gattineni J, Baum M. Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism. Pediatr Nephrol 2010; 25:591.</a></li><li><a class="nounderline abstract_t">Habra MA, Jimenez C, Huang SC, et al. Expression analysis of fibroblast growth factor-23, matrix extracellular phosphoglycoprotein, secreted frizzled-related protein-4, and fibroblast growth factor-7: identification of fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein as major factors involved in tumor-induced osteomalacia. Endocr Pract 2008; 14:1108.</a></li><li><a class="nounderline abstract_t">Berndt T, Thomas LF, Craig TA, et al. Evidence for a signaling axis by which intestinal phosphate rapidly modulates renal phosphate reabsorption. Proc Natl Acad Sci U S A 2007; 104:11085.</a></li><li><a class="nounderline abstract_t">Kawata T, Imanishi Y, Kobayashi K, et al. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol 2007; 18:2683.</a></li><li><a class="nounderline abstract_t">Tenenhouse HS, Murer H. Disorders of renal tubular phosphate transport. J Am Soc Nephrol 2003; 14:240.</a></li><li><a class="nounderline abstract_t">A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet 1995; 11:130.</a></li><li><a class="nounderline abstract_t">White KE, Carn G, Lorenz-Depiereux B, et al. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 2001; 60:2079.</a></li><li><a class="nounderline abstract_t">Hasani-Ranjbar S, Amoli MM, Ebrahim-Habibi A, et al. SLC34A3 intronic deletion in a new kindred with hereditary hypophosphatemic rickets with hypercalciuria. J Clin Res Pediatr Endocrinol 2012; 4:89.</a></li><li><a class="nounderline abstract_t">Prié D, Huart V, Bakouh N, et al. Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter. N Engl J Med 2002; 347:983.</a></li><li><a class="nounderline abstract_t">Lapointe JY, Tessier J, Paquette Y, et al. NPT2a gene variation in calcium nephrolithiasis with renal phosphate leak. Kidney Int 2006; 69:2261.</a></li><li><a class="nounderline abstract_t">Karim Z, Gérard B, Bakouh N, et al. NHERF1 mutations and responsiveness of renal parathyroid hormone. N Engl J Med 2008; 359:1128.</a></li><li><a class="nounderline abstract_t">Lorenz-Depiereux B, Bastepe M, Benet-Pagès A, et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 2006; 38:1248.</a></li><li><a class="nounderline abstract_t">Liu S, Zhou J, Tang W, et al. Pathogenic role of Fgf23 in Dmp1-null mice. Am J Physiol Endocrinol Metab 2008; 295:E254.</a></li><li><a class="nounderline abstract_t">Saito T, Shimizu Y, Hori M, et al. A patient with hypophosphatemic rickets and ossification of posterior longitudinal ligament caused by a novel homozygous mutation in ENPP1 gene. Bone 2011; 49:913.</a></li><li><a class="nounderline abstract_t">Brownstein CA, Adler F, Nelson-Williams C, et al. A translocation causing increased alpha-klotho level results in hypophosphatemic rickets and hyperparathyroidism. Proc Natl Acad Sci U S A 2008; 105:3455.</a></li><li><a class="nounderline abstract_t">Wilkins GE, Granleese S, Hegele RG, et al. Oncogenic osteomalacia: evidence for a humoral phosphaturic factor. J Clin Endocrinol Metab 1995; 80:1628.</a></li><li><a class="nounderline abstract_t">Riminucci M, Collins MT, Fedarko NS, et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 2003; 112:683.</a></li><li><a class="nounderline abstract_t">Bhan I, Shah A, Holmes J, et al. Post-transplant hypophosphatemia: Tertiary 'Hyper-Phosphatoninism'? Kidney Int 2006; 70:1486.</a></li><li><a class="nounderline abstract_t">Pande S, Ritter CS, Rothstein M, et al. FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. Nephron Physiol 2006; 104:p23.</a></li><li><a class="nounderline abstract_t">Ghanekar H, Welch BJ, Moe OW, Sakhaee K. Post-renal transplantation hypophosphatemia: a review and novel insights. Curr Opin Nephrol Hypertens 2006; 15:97.</a></li><li><a class="nounderline abstract_t">Evenepoel P, Naesens M, Claes K, et al. Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant 2007; 7:1193.</a></li><li><a class="nounderline abstract_t">Evenepoel P, Meijers BK, de Jonge H, et al. Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation. Clin J Am Soc Nephrol 2008; 3:1829.</a></li><li><a class="nounderline abstract_t">Lee HW, Suh KS, Kim J, et al. Hypophosphatemia after live donor right hepatectomy. Surgery 2008; 144:448.</a></li><li><a class="nounderline abstract_t">Salem RR, Tray K. Hepatic resection-related hypophosphatemia is of renal origin as manifested by isolated hyperphosphaturia. Ann Surg 2005; 241:343.</a></li><li><a class="nounderline abstract_t">Clarke BL, Wynne AG, Wilson DM, Fitzpatrick LA. Osteomalacia associated with adult Fanconi's syndrome: clinical and diagnostic features. Clin Endocrinol (Oxf) 1995; 43:479.</a></li><li><a class="nounderline abstract_t">Okada M, Imamura K, Iida M, et al. Hypophosphatemia induced by intravenous administration of Saccharated iron oxide. Klin Wochenschr 1983; 61:99.</a></li><li><a class="nounderline abstract_t">Fernández-Fernández FJ, Martín-Fernández A. Parenteral iron as a cause of hypophosphataemia. BMJ 2014; 349:g4616.</a></li><li><a class="nounderline abstract_t">Schouten BJ, Hunt PJ, Livesey JH, et al. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab 2009; 94:2332.</a></li><li><a class="nounderline abstract_t">Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res 2013; 28:1793.</a></li><li><a class="nounderline abstract_t">Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006; 354:2006.</a></li><li><a class="nounderline abstract_t">Owen S, Hatfield A, Letvak L. Imatinib and altered bone and mineral metabolism. N Engl J Med 2006; 355:627; author reply 628.</a></li><li><a class="nounderline abstract_t">Kempe DS, Dërmaku-Sopjani M, Fröhlich H, et al. Rapamycin-induced phosphaturia. Nephrol Dial Transplant 2010; 25:2938.</a></li><li><a class="nounderline abstract_t">Hutson TE, Figlin RA, Kuhn JG, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008; 13:1084.</a></li><li><a class="nounderline abstract_t">Bellini E, Pia A, Brizzi MP, et al. Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism. Ann Oncol 2011; 22:988.</a></li><li><a class="nounderline abstract_t">Broman M, Carlsson O, Friberg H, et al. Phosphate-containing dialysis solution prevents hypophosphatemia during continuous renal replacement therapy. Acta Anaesthesiol Scand 2011; 55:39.</a></li></ol></div><div id="topicVersionRevision">Topic 830 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6660029" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Severe hypophosphatemia--a hospital survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3603104" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Severe hypophosphatemia in a general hospital population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16194637" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Hypophosphatemia: an update on its etiology and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3122679" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Severe hypophosphatemia in hospitalized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10670405" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Severe hypophosphatemia. Pathophysiologic implications, clinical presentations, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8878151" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Hypophosphataemia: a dangerous disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15888903" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Refeeding syndrome and hypophosphatemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6843518" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : On the mechanism of hypophosphatemia during acute hyperventilation: evidence for increased muscle glycolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14105225" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : EFFECTS OF ALKALOSIS ON PLASMA CONCENTRATION AND URINARY EXCRETION OF INORGANIC PHOSPHATE IN MAN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2104562" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Hypophosphatemia complicating management of acute severe asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10781395" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Persistent, progressive hypophosphataemia after voluntary hyperventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17175888" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Hypophosphatemia and hungry bone syndrome in a dialysis patient with secondary hyperparathyroidism treated with cinacalcet--proposal for an improved monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19524963" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1498272" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Homer Smith Award. Cellular mechanisms in proximal tubular Pi reabsorption: some answers and more questions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8743494" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Renal brush border membrane Na/Pi-cotransport: molecular aspects in PTH-dependent and dietary regulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5636663" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Evidence for a phosphorus-depletion syndrome in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9688005" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The clinical implications of hypophosphatemia following major hepatic resection or cryosurgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20299362" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21496982" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Sustained hypophosphatemic effect of once-daily niacin/laropiprant in dyslipidemic CKD stage 3 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16735491" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17687185" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : New aspect of renal phosphate reabsorption: the type IIc sodium-dependent phosphate transporter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19387319" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Mechanisms of renal phosphate loss in liver resection-associated hypophosphatemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19669798" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19158050" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Expression analysis of fibroblast growth factor-23, matrix extracellular phosphoglycoprotein, secreted frizzled-related protein-4, and fibroblast growth factor-7: identification of fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein as major factors involved in tumor-induced osteomalacia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17566100" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Evidence for a signaling axis by which intestinal phosphate rapidly modulates renal phosphate reabsorption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17855636" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12506157" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Disorders of renal tubular phosphate transport.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7550339" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11737582" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22672866" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : SLC34A3 intronic deletion in a new kindred with hereditary hypophosphatemic rickets with hypercalciuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12324554" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16688119" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : NPT2a gene variation in calcium nephrolithiasis with renal phosphate leak.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18784102" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : NHERF1 mutations and responsiveness of renal parathyroid hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17033625" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18559986" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Pathogenic role of Fgf23 in Dmp1-null mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21745613" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A patient with hypophosphatemic rickets and ossification of posterior longitudinal ligament caused by a novel homozygous mutation in ENPP1 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18308935" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A translocation causing increased alpha-klotho level results in hypophosphatemic rickets and hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7745010" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Oncogenic osteomalacia: evidence for a humoral phosphaturic factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12952917" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16941023" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Post-transplant hypophosphatemia: Tertiary 'Hyper-Phosphatoninism'?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16691036" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16481873" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Post-renal transplantation hypophosphatemia: a review and novel insights.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17359508" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18922992" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18707044" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Hypophosphatemia after live donor right hepatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15650646" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Hepatic resection-related hypophosphatemia is of renal origin as manifested by isolated hyperphosphaturia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7586624" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Osteomalacia associated with adult Fanconi's syndrome: clinical and diagnostic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6843038" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Hypophosphatemia induced by intravenous administration of Saccharated iron oxide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25027747" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Parenteral iron as a cause of hypophosphataemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19366850" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23505057" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16687713" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Altered bone and mineral metabolism in patients receiving imatinib mesylate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16899786" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Imatinib and altered bone and mineral metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20368307" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Rapamycin-induced phosphaturia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18838439" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21321087" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21039362" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Phosphate-containing dialysis solution prevents hypophosphatemia during continuous renal replacement therapy.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
